glp-1 popularity Drug Market: the rapid growth of the diabetes and obesity drugs market The explosive popularity of GLP-1

The FDA requires a CVOT for all antidiabetic agents per its 2008 guidance, and a GLP-1-class CVOT is standard for obesity agents following SELECT (semaglutide 2.4 mg, N=17,604) which showed a 20% reduction in MACE [11]

Most evidence comes from standard therapeutic doses used for diabetes or obesity management

Being obese increases the risk of several serious conditions, including type 2 diabetes, cardiovascular disease, and certain cancers

In 2023 , the American Society of Anesthesiologists (ASA) suggested holding daily GLP-1 medicines on the day of surgery and weekly injections for a week before, out of concern for delayed gastric emptying

Mehal says

The question of whether semaglutide pills work as well as injections is more relevant than ever as more people seek sustainable ways to manage their metabolic health